Adolescent patient (13-17 years of age) with Schizophrenia research hub

2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia

This two-year study looks at the safety of a medicine called cariprazine (Reagila) in teenagers aged 13 to 17 with schizophrenia. Researchers want to see how well young people tolerate the drug, monitor any side effects, and check if it helps improve their symptoms over time.